Published in Cancer Res on September 01, 2002
Randomized Trial of Suicide Gene Therapy and Prostate Cancer (ReCAP) | NCT00583492
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther (2008) 1.67
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
Monitoring enzyme activity using a diamagnetic chemical exchange saturation transfer magnetic resonance imaging contrast agent. J Am Chem Soc (2011) 1.41
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem (2008) 1.33
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One (2008) 1.30
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 1.22
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther (2009) 1.16
Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther (2011) 1.14
Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther (2009) 1.13
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev (2010) 1.06
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther (2013) 1.04
Maize haplotype with a helitron-amplified cytidine deaminase gene copy. BMC Genet (2006) 1.04
Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther (2011) 0.98
Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther (2013) 0.97
Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine. J Mol Biol (2008) 0.91
Synthesis of a probe for monitoring HSV1-tk reporter gene expression using chemical exchange saturation transfer MRI. Nat Protoc (2013) 0.90
Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes. Adv Cancer Res (2012) 0.88
Increasing the efficacy of oncolytic adenovirus vectors. Viruses (2010) 0.88
Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors. Oncoimmunology (2015) 0.86
Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use. Int J Oncol (2011) 0.86
Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther (2008) 0.85
Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus. Virology (2007) 0.83
Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir. Cancer Gene Ther (2011) 0.82
Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus. Mol Ther (2013) 0.81
Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev (2015) 0.81
The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy. Cancers (Basel) (2013) 0.81
Development of viral vectors for gene therapy for chronic pain. Pain Res Treat (2011) 0.81
Oncolytic viruses: adenoviruses. Virus Genes (2017) 0.81
Chapter seven--Cancer treatment with gene therapy and radiation therapy. Adv Cancer Res (2012) 0.80
Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Curr Gene Ther (2012) 0.78
Molecular markers in prostate cancer. Part II: potential roles in management. Asian J Androl (2008) 0.78
Progress in gene therapy for prostate cancer. Front Oncol (2012) 0.78
Evaluation of adenovirus capsid labeling versus transgene expression. Virol J (2010) 0.78
Monitoring adenoviral based gene delivery in rat glioma by molecular imaging. World J Clin Oncol (2013) 0.78
Handling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses. J Vis Exp (2014) 0.78
Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy. PLoS One (2014) 0.78
Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer. Cancer Gene Ther (2013) 0.77
Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer. Mol Ther Oncolytics (2015) 0.77
Adenoviral gene therapy, radiation, and prostate cancer. Rev Urol (2005) 0.77
Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World J Urol (2003) 0.76
Polymeric oncolytic adenovirus for cancer gene therapy. J Control Release (2015) 0.76
An experimental study on cervix cancer with combination of HSV-TK/GCV suicide gene therapy system and 60Co radiotherapy. BMC Cancer (2010) 0.76
Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes. PLoS One (2014) 0.76
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Discovery of a bacterial 5-methylcytosine deaminase. Biochemistry (2014) 0.75
Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. Gene Ther (2016) 0.75
Caspase-9: structure, mechanisms and clinical application. Oncotarget (2017) 0.75
Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein. Cancer Gene Ther (2015) 0.75
Clinical experience with gene therapy for the treatment of prostate cancer. Rev Urol (2007) 0.75
Anti-proliferative Effect of Engineered Neural Stem Cells Expressing Cytosine Deaminase and Interferon-β against Lymph Node-Derived Metastatic Colorectal Adenocarcinoma in Cellular and Xenograft Mouse Models. Cancer Res Treat (2016) 0.75
Immune System, Friend or Foe of Oncolytic Virotherapy? Front Oncol (2017) 0.75
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58
Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res (2003) 4.29
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol (2010) 3.67
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol (2003) 3.54
Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol (2002) 3.52
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol (2011) 3.03
Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol (2010) 2.92
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. J Endourol (2014) 2.78
The mouse ascending: perspectives for human-disease models. Nat Cell Biol (2007) 2.74
Predictors of immediate continence following robot-assisted radical prostatectomy. J Endourol (2012) 2.71
Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia (2005) 2.68
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab (2005) 2.65
da Vinci-assisted robotic partial nephrectomy: technique and results at a mean of 15 months of follow-up. Eur Urol (2006) 2.65
Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res (2003) 2.61
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther (2007) 2.44
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43
The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2010) 2.39
A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J Neurosci Methods (2002) 2.35
Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke (2002) 2.24
Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach. J Urol (2012) 2.22
Robotic radical prostatectomy with the "Veil of Aphrodite" technique: histologic evidence of enhanced nerve sparing. Eur Urol (2006) 2.18
Temporal trends, practice patterns, and treatment outcomes for infected upper urinary tract stones in the United States. Eur Urol (2012) 2.16
Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery (2003) 2.16
Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis (2012) 2.15
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol (2005) 2.11
Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab (2006) 2.10
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
Evolution of robotic radical prostatectomy: assessment after 2766 procedures. Cancer (2007) 1.91
Vattikuti Institute prostatectomy: technique. J Urol (2003) 1.91
Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology (2004) 1.88
Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol (2010) 1.86
Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J (2007) 1.84
Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis (2012) 1.79
Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol (2009) 1.77
Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke. Circulation (2003) 1.77
Safety profile of robot-assisted radical prostatectomy: a standardized report of complications in 3317 patients. Eur Urol (2011) 1.76
Impact of percutaneous suprapubic tube drainage on patient discomfort after radical prostatectomy. Eur Urol (2009) 1.76
EMMA--mouse mutant resources for the international scientific community. Nucleic Acids Res (2009) 1.75
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Second hip fracture in older men and women: the Framingham Study. Arch Intern Med (2007) 1.72
Technique of da Vinci robot-assisted anatomic radical prostatectomy. Urology (2002) 1.71
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol (2011) 1.71
Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69
MRI detects white matter reorganization after neural progenitor cell treatment of stroke. Neuroimage (2006) 1.69
Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther (2008) 1.67
Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. J Cereb Blood Flow Metab (2007) 1.64
Marital status: a gender-independent risk factor for poorer survival after radical cystectomy. BJU Int (2012) 1.64
Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res (2002) 1.63
Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer (2007) 1.61
Robotic nephrectomy for the treatment of benign and malignant disease. BJU Int (2008) 1.60
Who's in favor of translational cell therapy for stroke: STEPS forward please? Cell Transplant (2009) 1.60
Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing: an analysis of 154 consecutive patients. BJU Int (2006) 1.59
A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. Eur Urol (2011) 1.57
One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke. Stroke (2007) 1.57
Stroke transiently increases subventricular zone cell division from asymmetric to symmetric and increases neuronal differentiation in the adult rat. J Neurosci (2004) 1.55
Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J Neurosci (2005) 1.54
Ca2+-dependent inhibition of NHE3 requires PKC alpha which binds to E3KARP to decrease surface NHE3 containing plasma membrane complexes. Am J Physiol Cell Physiol (2003) 1.53
Long-term functional urinary outcomes comparing single- vs double-layer urethrovesical anastomosis: two-year follow-up of a two-group parallel randomized controlled trial. Urology (2010) 1.52
Management of rectal injury during robotic radical prostatectomy. Urology (2011) 1.52
Adherence to the medical regime in patients with heart failure. Eur J Heart Fail (2010) 1.51
Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab (2006) 1.51
Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys (2006) 1.50
Maximizing console surgeon independence during robot-assisted renal surgery by using the Fourth Arm and TilePro. J Endourol (2009) 1.49